Adriana Rossi, MD
Testing for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning.
In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.
DOWNLOAD TRANSCRIPT
CLICK HERE to participate in our episode survey.
Mentioned on this episode:
Minimal/Measurable Residual DiseaseMinimal/Measurable Residual Disease Chart Tests (FISH, Flow Cytometry, Next-generation Sequencing)The Revolution of Genomics: How Testing Leads to Individualized Treatment Multiple MyelomaAcute Lymphoblastic LeukemiaAdditional LLS Support Resources:
Information Specialists Financial supportFree telephone/web patient programs Free booklets Clinical Trial Support CenterYoung Adult ResourcesCaregiver support Caregiver WorkbookSurvivorship WorkbookOnline chats LLS Community Support groups Patti Robinson Kaufmann First Connection Program Free Nutrition ConsultationsSupport for this episode provided by: Adaptive Biotechnologies
The post Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer first appeared on The Bloodline With Blood Cancer United Podcast.